Survodutide

At a glance

Overview

Known during development as BI 456906, survodutide combines two receptor activities in a long-acting peptide. Its development includes obesity trials in people with and without diabetes and liver studies in metabolic dysfunction-associated steatohepatitis. SYNCHRONIZE-1 results reported in 2026 provide phase 3 obesity evidence, moving beyond the earlier proof-of-concept studies. That progress does not itself establish marketing approval. The liver and obesity programs also answer separate questions: a reduction in body weight or liver fat is not automatically proof of improved fibrosis, prevention of cirrhosis or fewer cardiovascular events.

Supporting sources [1] [2] [3] [4]

How it works

GLP-1 receptor activity affects appetite, glucose-dependent insulin secretion and gastric emptying. Glucagon receptor activity adds hepatic and energy-expenditure effects. Survodutide’s design seeks to combine these actions into useful weight and liver responses while balancing glucose regulation. Because receptor balance, exposure and patient population differ among dual agonists, findings for another GLP-1/glucagon peptide cannot substitute for survodutide-specific trials.

Supporting sources [1] [2] [3] [4]

Distinct development programs

Obesity studies assess weight change and related outcomes, while MASH studies evaluate liver disease directly. Eligibility and background disease differ, so the programs should not be combined into a single undifferentiated metabolic-benefit claim.

Supporting sources [1] [2]

MASH phase 2 findings

A randomized liver trial found greater improvement in MASH without worsening fibrosis with survodutide than placebo. This supports activity on the prespecified histologic endpoint; it does not by itself demonstrate prevention of liver failure or a survival benefit.

Supporting sources [1]

Phase 3 obesity evidence

The 2026 SYNCHRONIZE-1 report describes greater body-weight reduction than placebo in adults with obesity without diabetes. The published study and sponsor announcement should be interpreted using their specified analysis and population, rather than informal cross-trial rankings.

Supporting sources [2] [3]

Tolerability considerations

Gastrointestinal adverse events were prominent in clinical development. Treatment discontinuation and exposure escalation affect both tolerability and reported efficacy. Larger studies and follow-up are needed to clarify uncommon risks and long-term use in patients with multiple comorbidities.

Supporting sources [1] [3]

What remains to be established

Positive late-stage results are part of an approval submission, not a final authorization. At this review date, survodutide is retained as investigational; the evidence does not validate a research supplier’s product or a self-directed combination with other metabolic medicines.

Supporting sources [2] [3]